A 51-year-old man with dilated cardiomyopathy was resuscitated from ventricular fibrillation. Twenty-days after using a wearable cardioverter-defibrillator (WCD) contact dermatitis with itching was evident and consistent with the self-gelling defibrillation electrodes patch on the back. Itching was controlled with clobetasol propionate application. The WCD was continued until catheter ablation and device implantation. The contact dermatitis was completely recovered two weeks after discontinuing the WCD. Among 58 patients using the WCD, three (5.2%) complained about discomfort with the device, and two (3.4%) complained of itching. Only the patient presented here (1.7%) suffered from contact dermatitis with itching. Contact dermatitis is rarely observed in patients wearing a WCD but physicians should be aware of this complication to maintain WCD compliance.
<Learning objective: Inappropriate wearing of a wearable cardioverter-defibrillator (WCD) is sometimes related to an unfortunate clinical course. WCD compliance is of paramount importance since wearing it correctly can prevent a life-threatening arrhythmia. Contact dermatitis is rarely observed in patients wearing a WCD but physicians should be aware of this complication to maintain WCD compliance.>
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiology Cases
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: a systematic review and meta-analysis.JACC Clin Electrophysiol. 2019; 5: 152-161
- Wearable cardioverter-defibrillators: A review of evidence and indications.Trends Cardiovasc Med. 2021; 31: 196-201
- Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD.Pacing Clin Electrophysiol. 2004; 27: 4-9
- Wearable cardioverter-defibrillator after myocardial infarction.N Engl J Med. 2018; 379: 1205-1215
- Anxiety, depression and quality of life in acute high risk cardiac disease patients eligible for wearable cardioverter defibrillator: Results from the prospective multicenter CRED-registry.PLoS One. 2019; 14e0213261
- Impairment of quality of life among patients with wearable cardioverter defibrillator therapy (LifeVest®): A preliminary study.Biomed Res Int. 2018; 276028494
Published online: November 30, 2021
Accepted: October 27, 2021
Received in revised form: October 6, 2021
Received: July 5, 2021
© 2021 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.